LL-37 is the only known human cathelicidin antimicrobial peptide, a 37-amino acid cationic peptide derived from the C-terminal region of the precursor protein hCAP18 (human cationic antimicrobial protein 18). It is produced by neutrophils, epithelial cells, and macrophages, serving as a front-line component of the innate immune system. Its name reflects its leucine-leucine N-terminal sequence and 37-amino acid length.
Researchers have studied LL-37 primarily for its broad-spectrum antimicrobial activity against bacteria, fungi, and enveloped viruses. Studies have examined its mechanism of membrane disruption through electrostatic attraction to negatively charged microbial membranes, followed by membrane permeabilization and cell death. Research has explored its ability to remain effective against both Gram-positive and Gram-negative bacteria through this physical membrane-disrupting mechanism rather than specific molecular targeting.
Beyond direct antimicrobial activity, researchers have studied LL-37’s immunomodulatory functions. Studies have examined its ability to recruit immune cells through chemokine receptor interactions and its role in modulating toll-like receptor (TLR) signaling pathways. Research has explored its potential anti-biofilm properties, wound healing activity through fibroblast and keratinocyte stimulation, and angiogenic effects relevant to tissue repair. Additional studies have investigated its potential role in cancer biology, where contradictory effects in different tumor models have generated significant research interest.
For research use only. Not for human consumption. Iron Prairie Labs products are intended for qualified researchers and laboratory use only.
